

I confirm that the Trust holds some of the information you requested. Please see the replies, set out against your questions:

1. *Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?* **66 patients in total.**
  
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
  - . *Locally advanced* **We do not record information within such a category.**
  - . *Recurrent metastatic* **\*5 or less**
  - . *Unknown Primary Diagnosis* **61 patients.**
  
- 3 Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
  - . Carboplatin (only or in combination with 5-FU) **1**
  - . Cisplatin (only or in combination with 5-FU) **0**
  - . Cetuximab with/without chemotherapy **\*5 or less**
  - . Cetuximab with radiotherapy **0**
  - . Pembrolizumab monotherapy **0**
  - . Pembrolizumab with chemotherapy **0**
  - . Nivolumab **\*5 or less**
  - . Docetaxel (only or in combination with 5-FU) **0**
  - . Fluorouracil (5FU) **0**
  - . Radiotherapy only **26**
  - . Other **57**
  
3. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
  - . Afibercept **0**
  - . Bevacizumab **0**
  - . Capecitabine **\*5 or less**
  - . CAPIRI **0**
  - . CAPOX **27**
  - . Cetuximab not in combination with FOLFIRI or FOLFOX **5**
  - . Cetuximab in combination with FOLFIRI **0**
  - . Cetuximab in combination with FOLFOX **0**
  - . Irinotecan **0**
  - . FOLFIRI **2**
  - . FOLFOX **0**
  - . Oxaliplatin **0**
  - . Panitumumab not in combination with FOLFIRI or FOLFOX **0**
  - . *Panitumumab in combination with FOLFIRI* **0**
  - . *Panitumumab in combination with FOLFOX* **0**
  - . *Nivolumab* **0**
  - . *Raltitrexed* **0**
  - . *Ramucirumab* **0**
  - . *Regorafenib* **0**
  - . *Sorafenib* **0**

- . *5FU only* **0**
- . *Tegafur Uracil + 5FU* **0**
- . *Trifluridine–tipiracil* **0**
- . *XELOX* **0**
- . *Other* **26**

**\*In accordance with the Freedom of Information Act, Exemption section 40 (Personal Information) has been applied. Due to the low numbers involved, 5 or fewer, we have withheld the exact numbers to protect the identities of individuals.**